Agios Pharmaceuticals Ownership | Who Owns Agios Pharmaceuticals?
Agios Pharmaceuticals Ownership Summary
Agios Pharmaceuticals is owned by 103.16% institutional investors, 1.50% insiders. Farallon capital management is the largest institutional shareholder, holding 9.97% of AGIO shares. BB Biotech AG Ord is the top mutual fund, with 6.16% of its assets in Agios Pharmaceuticals shares.
AGIO Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Agios Pharmaceuticals | 103.16% | 1.50% | -4.66% |
Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Farallon capital management | 5.67M | 9.97% | $186.46M |
Vanguard group | 5.63M | 9.89% | $185.05M |
Blackrock funding, inc. /de | 5.02M | 8.81% | $164.83M |
Blackrock | 4.86M | 8.55% | $209.52M |
Bellevue group | 3.52M | 6.17% | $115.51M |
Price t rowe associates inc /md/ | 2.42M | 4.26% | $79.64M |
Armistice capital | 2.26M | 3.98% | $74.41M |
State street | 2.15M | 3.78% | $70.72M |
Macquarie group | 1.68M | 2.96% | $55.37M |
Jefferies financial group | 1.50M | 2.63% | $49.29M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Caligan partners lp | 626.28K | 5.21% | $20.58M |
Cutter capital management, lp | 301.62K | 4.06% | $9.91M |
Eagle health investments lp | 330.83K | 2.67% | $10.87M |
Bellevue group | 3.52M | 2.22% | $115.51M |
Frazier life sciences management | 871.97K | 1.76% | $37.60M |
Patient square capital lp | 121.73K | 1.50% | $4.00M |
Bvf inc/il | 1.07M | 1.20% | $35.28M |
Armistice capital | 2.26M | 1.02% | $74.41M |
Farallon capital management | 5.67M | 0.95% | $186.46M |
Centerbook partners lp | 305.60K | 0.60% | $10.04M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Jefferies financial group | 1.50M | 0.29% | 1.50M |
Frazier life sciences management | 871.97K | 1.76% | 348.81K |
Adage capital partners gp | 303.00K | 0.02% | 303.00K |
Paradigm biocapital advisors lp | 276.44K | 0.32% | 276.44K |
Deutsche bank ag\ | 935.25K | 0.01% | 265.64K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
T. rowe price investment management | - | - | -928.60K |
Vestal point capital, lp | - | - | -760.00K |
Jpmorgan chase | 1.02M | 0.00% | -697.63K |
Marshall wace, llp | 631.63K | 0.03% | -631.66K |
Morgan stanley | 596.67K | 0.00% | -583.65K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Jefferies financial group | 1.50M | 0.29% | 1.50M | $49.29M |
Adage capital partners gp | 303.00K | 0.02% | 303.00K | $9.96M |
Paradigm biocapital advisors lp | 276.44K | 0.32% | 276.44K | $9.08M |
Casdin capital | 250.00K | 0.55% | 250.00K | $8.21M |
Norges bank | 145.09K | 0.00% | 145.09K | $4.77M |
Sold Out
Holder | Change |
---|---|
National bank of canada /fi/ | -1.00 |
Riverview trust | -11.00 |
Nelson, van denburg & campbell wealth management group | -11.00 |
Covestor | -12.00 |
Innealta capital | -17.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 231 | 4.05% | 58,738,591 | 1.40% | 103 | 1.00% | 126 | 22.33% | 70 | 2.94% |
Sep 30, 2024 | 222 | 1.83% | 57,925,704 | 3.66% | 101 | 1.05% | 104 | 1.96% | 66 | -15.38% |
Jun 30, 2024 | 218 | 9.00% | 55,883,066 | -6.01% | 98 | 0.88% | 102 | -0.97% | 78 | 39.29% |
Mar 31, 2024 | 200 | 11.73% | 59,453,348 | 2.90% | 105 | 0.98% | 103 | 9.57% | 56 | 12.00% |
Dec 31, 2023 | 179 | 15.48% | 57,776,522 | 1.07% | 103 | 0.99% | 94 | 40.30% | 50 | 6.38% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
BB Biotech AG Ord | 3.52M | 6.16% | -220.76K |
Vanguard Total Stock Mkt Idx Inv | 1.79M | 3.13% | 1.28K |
Vanguard US Total Market Shares ETF | 1.79M | 3.12% | 2.35K |
iShares Russell 2000 ETF | 1.49M | 2.59% | -12.87K |
Macquarie Small Cap Core I | 1.47M | 2.57% | 93.17K |
Vanguard Small Cap Index | 1.46M | 2.54% | 1.20K |
Delaware Small Cap Core I | 1.38M | 2.42% | -8.55K |
SPDR® S&P Biotech ETF | 1.15M | 2.00% | -12.29K |
T. Rowe Price Health Sciences | 1.11M | 1.94% | 40.10K |
Polar Capital Biotech S Inc | 1.00M | 1.75% | - |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Apr 10, 2025 | FOUSE JACQUALYN A | - | Sell | $194.17K |
Mar 03, 2025 | Burns James William | Chief Legal Officer | Sell | $40.41K |
Mar 03, 2025 | Burns James William | Chief Legal Officer | Sell | $42.19K |
Mar 03, 2025 | Burns James William | Chief Legal Officer | Sell | $59.74K |
Mar 03, 2025 | Jones Cecilia | Chief Financial Officer | Sell | $59.74K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q2 | - | 1 |
2025 Q1 | - | 16 |
2024 Q4 | - | 9 |
2024 Q3 | - | 3 |
2024 Q2 | - | 3 |
AGIO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools